Technology transfer is a critical step in pharmaceutical development. It bridges the gap between product development and commercial manufacturing, ensuring that a process developed in research or pilot facilities can be reproduced consistently at a manufacturing site.
For biotech and pharmaceutical companies, this transition involves more than simply replicating a manufacturing process. It requires transferring scientific knowledge, operational procedures, analytical methods, and quality systems in a structured and compliant way.
Regulatory agencies such as the U.S. Food and Drug Administration and the European Medicines Agency place strong emphasis on quality oversight during technology transfer. Regulators expect organizations to demonstrate that product quality, safety, and efficacy remain unchanged as manufacturing responsibilities move between teams, facilities, or organizations.
Companies that approach technology transfer with strong Quality Management System (QMS) frameworks are more likely to avoid regulatory delays, manufacturing inconsistencies, and operational disruptions.
Quality Risk Management in Technology Transfer: Common Failures and Fixes
Technology transfer often looks complete on paper—protocols approved, documents signed, timelines met. Yet during execution, we often see deviations, rework, or delayed validation because risk was not fully understood or managed across sites.
Quality Risk Management (QRM) is not just a regulatory expectation under International Council for Harmonization (ICH) Q9, it is a practical tool to anticipate where transfer breakdowns occur and reduce downstream impact.
Where QRM Breaks Down in Tech Transfer
1. Superficial Risk Assessments
Risk assessments are completed as a formality, often too high-level to guide execution.
- Limited input from manufacturing, QC, or engineering
- No linkage to critical process parameters (CPPs) or critical quality attributes (CQAs)
- Generic risk scoring without site-specific context
Impact: Issues emerge during scale-up or validation, requiring late-stage fixes.
2. Incomplete Process Understanding Transfer
The sending site assumes process knowledge is fully captured in documents.
- Tacit knowledge not transferred (operator experience, unwritten adjustments)
- Scale-dependent risks not assessed
- Differences in equipment or utilities overlooked
Impact: Process variability increases at the receiving site.
3. Misaligned Risk Ownership
Risk ownership is unclear between sending and receiving sites.
- No defined accountability for mitigation actions
- Risks identified but not tracked through closure
- Cross-functional gaps (QA, MSAT, QC)
Impact: Known risks remain open and resurface during execution.
4. Poor Integration with Validation Strategy
QRM outputs are not effectively used to shape validation.
- Critical risks not translated into validation parameters
- Sampling plans not risk-based
- Continued process verification (CPV) not aligned
Impact: Validation gaps, unexpected deviations, and regulatory observations.
5. Static Risk Management Approach
Risk assessments are treated as one-time exercises.
- No updates after engineering runs or initial batches
- Deviations and learnings not fed back into risk models
- No lifecycle approach
Impact: Repeated issues across batches and delayed stabilization.
Practical Fixes That Strengthen QRM
1. Build Risk Assessments Around Process Reality
- Use structured tools like FMEA with cross-functional input
- Anchor risks to CPPs, CQAs, and process steps
- Include site-specific variables (equipment, environment, operators)
2. Transfer Knowledge, Not Just Documents
- Conduct detailed knowledge transfer sessions (KT workshops)
- Capture tacit knowledge through SMEs and operators
- Use process mapping and failure mode walkthroughs
3. Define Clear Risk Ownership
- Assign risk owners for each identified risk
- Track mitigation actions with timelines
- Integrate into project governance and reporting
4. Link QRM to Validation and CPV
- Translate high-risk areas into validation focus points
- Align sampling, IPCs, and acceptance criteria with risk levels
- Use early batch data to refine risk assessments
5. Apply a Lifecycle QRM Approach
- Update risk assessments after each key milestone
- Integrate deviation trends and batch data
- Maintain a live risk register through commercial scale
A Pattern We Often See
In one transfer, a biologics process moved smoothly through documentation review but failed initial PPQ batches due to variability in mixing performance. The root cause was not equipment failure but an unassessed difference in impeller design between sites.
The risk had been “identified” at a high level but never translated into a mitigation or validation requirement.
A revised QRM approach focused on equipment equivalency and process dynamics helped stabilize the process within two additional runs.
How BioBoston Consulting Supports Technology Transfer
We support pharma and biotech teams in strengthening QRM during technology transfer by:
- Facilitating risk assessments aligned with ICH Q9
- Connecting QRM outputs to validation and CPV strategies
- Supporting cross-site alignment and governance
- Helping teams build practical, inspection-ready risk documentation
Preparing for a technology transfer between development and manufacturing teams?
Connect with BioBoston Consulting to discuss how experienced consultants can help strengthen planning and reduce operational risk.